A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors (NCT06561685)
An Open-label, Multicenter Study of LY4050784, a Selective SMARCA2/BRM Inhibitor, in Advanced Solid Tumor Malignancies With SMARCA4/BRG1 Alterations
π©Ί Plain-English Summary (8th-Grade Level)
The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMARCA4) alteration who have previously received, do not qualify for, or are refusing standard of care treatments, or there is no standard therapy available for the disease. The study is conducted in two parts - phase Ia (dose-escalation) and phase Ib (dose-optimization, dose-expansion). The study will last up to approximately 4 years.
Who can join: Review the eligibility criteria below.
Location: UCLA β Santa Monica, California
Age range: 18 Years
π§ͺ Interventions in This Study
π "Do I Qualify?" β 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria β
π All Participating Trial Locations (33 Sites)
Showing the first 25 of 33 sites.
- UCLA β Santa Monica, California
- University of Colorado Health Hospital β Aurora, Colorado
- Sarah Cannon Research Institute at HealthOne β Denver, Colorado
- Florida Cancer Specialists ORLANDO/DDU β Lake Mary, Florida
- University of Miami β Miami, Florida
- University of Chicago β New Lenox, Illinois
- Massachusetts General Hospital β Boston, Massachusetts
- Dana-Farber Cancer Institute β Boston, Massachusetts
- Columbia University Medical Center β New York, New York
- Memorial Sloan Kettering Cancer Center β New York, New York
- Ohio State University Hospital β Columbus, Ohio
- Sarah Cannon Research Institute β Nashville, Tennessee
- SCRI Oncology Partners β Nashville, Tennessee
- Vanderbilt-Ingram Cancer Center β Nashville, Tennessee
- MD Anderson Cancer Center β Houston, Texas
- USO-Virginia Cancer Specialists, PC β Fairfax, Virginia
- Medical College of Wisconsin β Milwaukee, Wisconsin
- Institut Bergonie β Bordeaux,
- Institut Curie β Paris,
- Institut Gustave Roussy-Gustave Roussy Cancer Center -DITEP β Villejuif,
- Charite-Universitatsmedizin Berlin β Berlin,
- Universitaetsklinikum Essen β Essen,
- Krankenhaus Nordwest β Frankfurt am Main,
- National Cancer Center Hospital β ChΕ«Εku,
- National Cancer Center Hospital East β Kashiwa,
π Contact the Study Coordinator
Phone: (317) 615-4559
Email: LillyTrials@Lilly.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
π° Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA Β§ 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Solid Tumor
- A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors β Orlando, Florida
- Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS β Coral Gables, Florida
- Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM) β Baltimore, Maryland
- TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) β Los Angeles, California
- Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors β Anchorage, Alaska
- QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors β El Segundo, California
Explore by condition: All Metastatic Solid Tumor clinical trials
π‘ How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.